PEOPLE - Changes at Cytogen:
This article was originally published in Clinica
Executive Summary
Dr Thomas McKearn has stepped down from his role as chairman, president and CEO of Cytogen. Board member William Mills has been appointed to take on the role as chairman and John Bagalay will act as interim president and CEO in addition to his current role as interim CFO. The US company develops products for the targeted delivery of diagnostics and therapeutic substances to disease sites.